Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
16.03
-0.17 (-1.05%)
At close: Oct 30, 2026, 4:00 PM EDT
15.98
-0.05 (-0.32%)
After-hours: Oct 30, 2026, 7:56 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
12.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.60B |
| BioMarin Pharmaceutical | 3.41B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
| Caris Life Sciences | 989.61M |
| BridgeBio Pharma | 945.54M |
SMMT News
- 6 days ago - Summit, Lunit announce research agreement to evaluate Lunit SCOPE IO - TheFly
- 6 days ago - Summit’s partner announces results from Phase III HARMONi-GI1 study - TheFly
- 6 days ago - Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China - Business Wire
- 8 days ago - Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development - PRNewsWire
- 8 days ago - Summit Therapeutics, Lunit announces research pact over Lunit SCOPE IO - TheFly
- 8 days ago - Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development - Business Wire
- 10 days ago - Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026 - Business Wire
- 11 days ago - Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer - PRNewsWire